Cited 6 times since 2014 (0.6 per year) source: EuropePMC Pharmacogenomics, Volume 15, Issue 11, 1 1 2014, Pages 1471-1477 No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Leusink M, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH
Aim
Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins.
Patients & methods
We analyzed the interaction between the *22 minor allele and statin use in the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, using logistic and Cox regression models.
Results
In total, 771 MI cases and 6131 controls were included in the analyses. There was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the estimates from both studies were combined (interaction odds ratio: 1.27; 95% CI: 0.73-2.21; p = 0.40 for carriers of the minor T-allele).
Conclusion
We found no association of the CYP3A4*22 minor allele (rs35599367) with the effectiveness of statins in reducing MI risk.
